期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

宫颈鳞状细胞癌化疗前后骨桥蛋白变化及与化疗效果的关系 被引量：3

下载PDF
导出
摘要 目的探讨TP方案新辅助化疗对宫颈鳞癌组织中骨桥蛋白(OPN)表达的影响。方法以34例Ⅰb2(18例)～Ⅱa期(16例)的宫颈鳞状细胞癌患者为研究对象,TP方案化疗2个疗程后行宫颈癌根治术,免疫组化法检测化疗前后组织中OPN表达及与化疗效果的关系。结果 (1)全组病例化疗前后OPN阳性表达率分别为85.29%(29/34)和61.76%(21/34),表达强度差异有统计学意义(P=0.007);(2)临床分期为Ⅰb2期、Ⅱa期、年龄>45岁者化疗前后OPN的阳性表达差异无统计学意义;年龄≤45岁、病理提示高中分化及低分化者化疗后OPN的阳性表达较前明显降低(P<0.05);(3)新辅助化疗总有效率67.65%(23/34),其中完全缓解率52.94%(18/34),部分缓解率23.53%(8/34)。结论 TP方案新辅助化疗能总体上降低宫颈鳞状细胞患者组织中OPN表达强度,延缓宫颈癌病情进展。OPN在宫颈癌组织中的表达强度与化疗敏感性及化疗效果有关,化疗前检测宫颈鳞状细胞癌组织中OPN的表达强度可能对预测宫颈鳞癌新辅助化疗敏感性有帮助。
作者 吴婷婷 关婷
机构地区 广州军区广州总医院妇产科
出处 《广东医学》 CAS CSCD 北大核心 2011年第12期1597-1599,共3页 Guangdong Medical Journal
关键词 宫颈鳞状细胞癌 卡铂 紫杉醇 化疗 OPN
分类号 R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1NAPOLITANOD U, IMPERATO F, MOSSA B, et al. The role of neoadjuvant chemotherapy for squamous cell cervical ( I b - Ⅲ b) : a long - term randomized trial [ J ]. Eur J Gynaecol Oncol, 2003, 24(1) : 51 -59.
  • 2DESOUZA N M, SOUTTER W P, RUSTIN G, et al. Use of neo- adjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumor shrinkage and molecular profile on mag- netic resonance and assessment of 3 - year outcome [J]. Br J Cancer, 2004, 90 ( 12 ) : 2326 - 2331.
  • 3CHO H, HONG S W, OH Y J, et al. Clinical significance ofos- teopontin expression in cervical cancer[ J ]. J Cancer Res Clin On- col, 2008, 134(8) : 909 -917.
  • 4朱耀魁,屈洋,夏明翰,王晓玉,罗新.骨桥蛋白在子宫内膜癌及子宫颈癌组织中的表达[J].中国病理生理杂志,2005,21(12):2414-2417. 被引量：31

二级参考文献10

  • 1Chambers AF,Wilson SM,Kerkvlies N,et al.Osteopontin expression in Iung cancer[J].Lung Cancer,1996,15(10):311 - 323.
  • 2Webber GF.The metastasis gene osteopontin:a candidate target for cancer therapy[J].Biochimica et Biophysica Acta,2001,1552(1):61 - 85.
  • 3Sharp JA,Sung V,Slavin J,et al.Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer[J].Lab Invest,1999,79(8):869-877.
  • 4Michihiro Hirana,Fumiyuki Takahashi,Kazuhisa Takahashi,et al.Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth [J].Cancer Lett,2003,198(2):107-117.
  • 5SungV,GillesC,MurrayA,etal.The LCC15- MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype[J].Exp Cell Res,1998,241(4):273 - 284.
  • 6Senger DR,Perruzzi CA.Cell migration promoted by a potent GRGDS- containing thrombin- cleavage fragment of osteopontin[J].Biochimica et Biophysica Acta,1996,1314(1):13 - 24.
  • 7Weber GF,Ashkar S.Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers[J].Brain Res Bull,2000,53(4):421-424.
  • 8Naor D,Sionov RV,Ish- Shalom D.CD44:structure,function,and associaton with the malignant process [J].Adv Cancer Res,1997,77(4):241 - 319.
  • 9Scott JA,Weir ML,Wilson SM,et al.Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue [J].Am J Physiol,1998,275(11):H2258 - H2265.
  • 10刘思金,胡国法,刘思国,魏影允,薛延,劳为德.人类骨桥蛋白(hOPN)在细胞增殖中的功能研究[J].高技术通讯,2003,13(2):25-28. 被引量：23

共引文献30

同被引文献40

  • 1朱耀魁,屈洋,夏明翰,王晓玉,罗新.骨桥蛋白在子宫内膜癌及子宫颈癌组织中的表达[J].中国病理生理杂志,2005,21(12):2414-2417. 被引量：31
  • 2Friedlander ML,Atkinson K,Coppleson JV,et al.The integration of chemotherapy into the manage-ment of locally anvanced cervical cancer:a pilot study[J].Gynecol Oncol,1984,19(1):1-7.
  • 3Cai HB,Chen HZ,Yin HH.Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer[J].J Obstet Gynecol Res,2006,32(3):315-323.
  • 4Barrel DP.MicroRNAs:genomics,biogenesis,mechanism,and function[J].Cell,2004,116(2):281-297.
  • 5Rossi L,Bonmassar E,Faraoni I.Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro[J].Pharmacol Res,2007,56(3):248-253.
  • 6Meng F,Henson R,Lang M,et al.Involvement of human MicroRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines[J].Gastroenterology,2006,130(7):2113-2119.
  • 7Garzon R,Pichiorri F,Palumbo T,et al.MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia[J].Oncogene,2007,26(28):4148-4157.
  • 8Blower PE,Verducci JS,Lin S,et al.MicroRNA expression profile for the NCL-60 cancer cell panel [J].Mol Cancer Ther,2007,6(5):1483-1491.
  • 9Blower PE,Chung JH,Verducci JS,et al.MicroRNAs modulate the chemosensity of tumor cells[J].Mol Cancer Ther,2008,7(1):1-9.
  • 10Nakajima G,Hyashi K,Xi Y,et al.Non-coding microRNAs has-Let-7g and has-miR-181b are associated with chemoresponse to S-1 in colon cancer [J].Cancer Genomics Proteomics,2006,3(5):317-324.

二级引证文献8

广东医学
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部